BRIEF-GlaxoSmithKline says Dolutegravir granted FDA priority review

LONDON Fri Feb 15, 2013 10:16am EST

Related Topics

LONDON Feb 15 (Reuters) - GlaxoSmithKline Plc : * Dolutegravir granted FDA priority review * FDA has assigned Dolutegravir a prescription drug user fee act (PDUFA) target

date of 17 August 2013 * Viiv Healthcare announces FDA priority review designation for dolutegravir as

a potential treatment for hiv infection * Source text

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.